Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 4, 2013

View Archived Issues

SK Chemical advances influenza vaccine into phase III development

Improved antiplatelet therapy for the novel P2Y1 blocker BMS-884775

Researchers in Hungary present novel chimeric fusion proteins for cancer

Takeda Pharmaceutical presents new agents for diabetes

Merck & Co. discloses new DPP IV inhibitors

Scientists at Siga Technologies synthesize novel agents for viral infections

New CYP11B2/CYP11B1 inhibitors patented by Roche

GSK receives European marketing authorization for Tafinlar

First launch of Marqibo in the U.S.

Amgen begins first-in-human study of AMG-282

Topline results from phase II ETC-1002 trial reported

Investigators begin phase I trial of ONT-380 in combination with trastuzumab

Extract from Calendula officinalis flowers improves memory, learning and attention in rodents

Tetraphase begins phase III trial of eravacycline in complicated intra-abdominal infections

Santhera Pharmaceuticals agrees with Takeda to license back European rights to Catena

Siltuximab applications submitted to FDA and EMA for multicentric Castleman disease

Zalicus completes patient enrollment in two phase II studies of Z-160

Novartis receives E.U. approval for Ilaris in active systemic juvenile idiopathic arthritis

Sanwa Kagaku Kenkyusho announces first launch of topiroxostat in Japan

Microsphere-encapsulated antagomir-92a shows promise in animal models of MI

GSK files application in Japan seeking approval for tenofovir in chronic hepatitis B

Imaxio reports on first human trial using IMX-313 in tuberculosis

TRAVERSE study of Pexa-Vec in advanced liver cancer fails to meet primary endpoint

Shionogi launches Irtra in Japan

Researchers present results from phase III SERAPHIN trial

Elan begins phase IIa study of ELND-005 for Down syndrome

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...